Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX ...

Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) ...

AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Samba TV, a specialist in AI-driven media intelligence, has released its H1 2025 State of Advertising report revealing a ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Arcutis ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...